Drug Trial Radar · NCT00521950
Cost-effectiveness of TPMT Pharmacogenetics
Last checked: Nov 20, 2026Latest source record: Mar 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
853
Actual
Start
Sep 2007
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Radboud University Medical Center
- First posted
- Aug 28, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether thiopurine S-methyltransferase (TPMT) genotyping prior to thiopurine use is cost-effective in patients with inflammatory bowel disease (IBD) in need of immune suppression. The study is designed to test the hypothesis that optimization of initial thiopurine dose based on pre-treatment TPMT genotyping will maximize treatment efficacy and minimize adverse drug reactions (ADRs) resulting in reduced costs.
Conditions
- Inflammatory Bowel Diseases
- Crohn Disease
- Ulcerative Colitis
Interventions
TPMT genotyping; Drug: azathioprine or 6-mercaptopurineGenetic
Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT\*2, \*3A, \*3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity. Patients are advised an initial treatment dose based on the enzyme activity: * Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care); * Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day; * Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;
azathioprine (AZA) or 6-mercaptopurine (6-MP)Drug
Patients will be advised a standard initial treatment dose: * AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);
Primary outcomes
What the sponsor says the trial is designed to measure.
- Haematological adverse drug reactionsTime frame: 0-5 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Bernhoven Hospital
Oss, Netherlands
Bernhoven Hospital
Veghel, Netherlands
Radboud University Medical Center
Nijmegen, Gelderland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.